Nanjing Hicin Pharmaceutical Co Ltd Working Capital to Net Assets Ratio
Nanjing Hicin Pharmaceutical Co Ltd working capital to net assets ratio. Nanjing Hicin Pharmaceutical Co Ltd (300584) has a Working Capital to Net Assets ratio of 5.4% as of June 2026. Working capital of CN¥60.09 Million (current assets of CN¥383.85 Million minus current liabilities of CN¥323.76 Million) is measured against net assets of CN¥1.12 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Nanjing Hicin Pharmaceutical Co Ltd (2012–2025)
Working capital to net assets ratio of Nanjing Hicin Pharmaceutical Co Ltd from 2012 to 2025. This chart shows how Nanjing Hicin Pharmaceutical Co Ltd's Working Capital to Net Assets ratio has evolved across 14 annual periods from 2012 to 2025. As of June 2026, the ratio stands at 5.4%, reflecting working capital of CN¥60.09 Million against net assets of CN¥1.12 Billion CNY. Explore Nanjing Hicin Pharmaceutical Co Ltd long-term investment allocation to see how much of total assets are deployed in long-term investments.
Nanjing Hicin Pharmaceutical Co Ltd Working Capital to Net Assets Ratio by Year (2012–2025)
Nanjing Hicin Pharmaceutical Co Ltd working capital to net assets ratio by year from 2012 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for Nanjing Hicin Pharmaceutical Co Ltd from 2012 to 2025, covering 14 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see balance sheet size of Nanjing Hicin Pharmaceutical Co Ltd.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 1.4% | CN¥15.38 Million | CN¥1.10 Billion | CN¥384.32 Million | CN¥368.94 Million | ▼ -0.7 pp |
| 2024 | 2.1% | CN¥21.80 Million | CN¥1.04 Billion | CN¥357.15 Million | CN¥335.35 Million | ▲ +4.4 pp |
| 2023 | -2.3% | CN¥-22.97 Million | CN¥987.50 Million | CN¥377.30 Million | CN¥400.27 Million | ▼ -8.8 pp |
| 2022 | 6.5% | CN¥61.33 Million | CN¥950.57 Million | CN¥378.38 Million | CN¥317.05 Million | ▲ +6.4 pp |
| 2021 | 0.1% | CN¥530.04K | CN¥948.48 Million | CN¥301.96 Million | CN¥301.43 Million | ▼ -16.6 pp |
| 2020 | 16.6% | CN¥112.77 Million | CN¥678.97 Million | CN¥293.74 Million | CN¥180.97 Million | ▼ -4.4 pp |
| 2019 | 21.0% | CN¥137.53 Million | CN¥653.98 Million | CN¥343.17 Million | CN¥205.63 Million | ▼ -0.2 pp |
| 2018 | 21.2% | CN¥123.08 Million | CN¥580.93 Million | CN¥282.69 Million | CN¥159.61 Million | ▼ -19.4 pp |
| 2017 | 40.6% | CN¥210.09 Million | CN¥517.68 Million | CN¥315.09 Million | CN¥105.00 Million | ▲ +31.0 pp |
| 2016 | 9.6% | CN¥26.44 Million | CN¥276.11 Million | CN¥111.49 Million | CN¥85.05 Million | ▼ -3.4 pp |
| 2015 | 12.9% | CN¥30.42 Million | CN¥235.08 Million | CN¥108.36 Million | CN¥77.94 Million | ▲ +4.3 pp |
| 2014 | 8.6% | CN¥17.24 Million | CN¥200.15 Million | CN¥100.26 Million | CN¥83.02 Million | ▼ -4.5 pp |
| 2013 | 13.1% | CN¥21.68 Million | CN¥165.93 Million | CN¥86.56 Million | CN¥64.88 Million | ▼ -13.2 pp |
| 2012 | 26.3% | CN¥34.89 Million | CN¥132.65 Million | CN¥81.81 Million | CN¥46.92 Million | — |